(VIANEWS) – IEP INVEST (IEP.BR), SCOR SE (SCR.PA), IMMO MOURY (IMMOU.BR) have the highest dividend yield stocks on this list.
| Financial Asset | Forward Dividend Yield | Updated (EST) |
|---|---|---|
| IEP INVEST (IEP.BR) | 100.81% | 2023-04-07 04:15:20 |
| SCOR SE (SCR.PA) | 6.7% | 2023-04-07 04:03:45 |
| IMMO MOURY (IMMOU.BR) | 4.48% | 2023-04-06 07:15:26 |
| ORKLA (ORK.OL) | 4.08% | 2023-04-05 07:34:34 |
| SANOFI (SAN.PA) | 3.55% | 2023-04-07 04:03:25 |
| DEKUPLE (DKUPL.PA) | 3.42% | 2023-04-07 04:48:16 |
| CEGEDIM (CGM.PA) | 2.63% | 2023-04-06 07:46:09 |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. IEP INVEST (IEP.BR)
100.81% Foward Dividend Yield
IEP INVEST’s last close was €5.10, 54.46% under its 52-week high of €11.20. Intraday change was 2%.
Iep Invest, NV is an investment firm specializing in investments in and loans to real estate companies. The firm previously operated as manufacturing group. It was formerly known as Punch International nv and changed its name to Iep Invest, NV in May 2014. Iep Invest, NV was founded in 1982 and is based in Antwerp, Belgium.
Earnings Per Share
As for profitability, IEP INVEST has a trailing twelve months EPS of €0.88.
PE Ratio
IEP INVEST has a trailing twelve months price to earnings ratio of 8.2. Meaning, the purchaser of the share is investing €8.2 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.66%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Oct 3, 2022, the estimated forward annual dividend rate is 5 and the estimated forward annual dividend yield is 100.81%.
Volatility
IEP INVEST’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.33%, a negative 0.09%, and a positive 2.37%.
IEP INVEST’s highest amplitude of average volatility was 1.66% (last week), 1.81% (last month), and 2.37% (last quarter).
Moving Average
IEP INVEST’s worth is under its 50-day moving average of €5.22 and way under its 200-day moving average of €7.34.
More news about IEP INVEST.
2. SCOR SE (SCR.PA)
6.7% Foward Dividend Yield
SCOR SE’s last close was €21.94, 24.81% under its 52-week high of €29.18. Intraday change was 2.14%.
SCOR SE, together with its subsidiaries, provides life and non-life reinsurance products in Europe, the Middle East, Africa, the Americas, Latin America, and Asia Pacific. It operates through two segments, SCOR Global P&C and SCOR Global Life. The SCOR Global P&C segment offers reinsurance products in the areas of property, motors, casualty treaties, credit and surety, decennial insurance, aviation, marine and energy, engineering, agricultural risks, and property catastrophes; specialties insurance products, including business solutions, political and credit risks, cyber, and environmental impairment liability; and business ventures and partnerships. The SCOR Global Life segment provides life reinsurance products, including protection for mortality, morbidity, behavioral risks, disability, long-term care, critical illness, medical, and personal accident. This segment also provides financial solutions that combine traditional life reinsurance with financial components and provide liquidity, balance sheet, solvency, and income improvements to clients; longevity solutions that include products covering the risk of negative deviation from expected results due to the insured or annuitant living longer than assumed in the pricing of insurance covers provided by insurers or pension funds; and distribution solutions. In addition, it is involved in the asset management business. The company was founded in 1970 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SCOR SE has a trailing twelve months EPS of €1.25.
PE Ratio
SCOR SE has a trailing twelve months price to earnings ratio of 17.55. Meaning, the purchaser of the share is investing €17.55 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.42%.
Volatility
SCOR SE’s last week, last month’s, and last quarter’s current intraday variation average was a positive 1.18%, a negative 0.60%, and a positive 1.88%.
SCOR SE’s highest amplitude of average volatility was 1.18% (last week), 2.06% (last month), and 1.88% (last quarter).
Yearly Top and Bottom Value
SCOR SE’s stock is valued at €21.94 at 17:50 EST, way under its 52-week high of €29.18 and way higher than its 52-week low of €13.31.
Revenue Growth
Year-on-year quarterly revenue growth declined by 39.5%, now sitting on 16.06B for the twelve trailing months.
Sales Growth
SCOR SE’s sales growth is negative 17.2% for the present quarter and negative 19.6% for the next.
More news about SCOR SE.
3. IMMO MOURY (IMMOU.BR)
4.48% Foward Dividend Yield
IMMO MOURY’s last close was €39.20, 17.99% below its 52-week high of €47.80. Intraday change was -1.01%.
Immo Moury SCA is a real estate investment trust. Immo Moury SCA is based in Belgium.
Earnings Per Share
As for profitability, IMMO MOURY has a trailing twelve months EPS of €2.92.
PE Ratio
IMMO MOURY has a trailing twelve months price to earnings ratio of 13.42. Meaning, the purchaser of the share is investing €13.42 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.16%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, IMMO MOURY’s stock is considered to be overbought (>=80).
More news about IMMO MOURY.
4. ORKLA (ORK.OL)
4.08% Foward Dividend Yield
ORKLA’s last close was kr76.48, 10.23% under its 52-week high of kr85.20. Intraday change was 2.58%.
Orkla ASA engages in branded consumer goods, and industrial and financial investment businesses. The company offers branded products, including frozen pizza, ketchup, soups, sauces, bread toppings, and ready-to-eat meals through grocery channels, as well as food service, convenience stores, and petrol stations. It also provides confectionery, biscuit, and snack products; and develops bran and crispbread products, as well as energy snack meals. In addition, the company offers personal care and cleaning products; dietary supplement, sport nutrition, and weight control products; wound care products and first aid equipment; painting tools; basic and wool garments for men, women, and children; and professional cleaning products. Further, it operates Gymgrossisten, Proteinfabrikken, Bodystore, and Fitnessmarket e-commerce portals for health and sports nutrition products; and restaurants. Additionally, the company supplies margarine and butter blends, bread and cake improvers and mixes, yeast, marzipan, and ice cream ingredients; produces and supplies hydro power to the Nordic power market; and develops and sells real estate properties. It offers its food products under the Grandiosa, TORO, Stabburet, Felix, Paulúns, NATURLI', Abba, Beauvais, Den Gamle Fabrik, Spilva, and Vitana brands; confectionery and snacks under the KiMs, Nidar, Stratos, Sætre, Göteborgs Kex, OLW, Panda, Laima, Selga, Taffel, Kalev, and Nói Síríus brands; health and sports nutrition under e Zalo, Jif, Bliw, Grumme, Blenda, Define, Möller's, Collett, Nutrilett, Maxim, Norgesplaster, and Salvequick brands; and food ingredients under the Odense, Mors Hjemmebakte, KronJäst, Bakkedal, and NATURLI brands. It has operations in Norway, Sweden, Denmark, Finland, Iceland, the Baltics, rest of Europe, and internationally. The company was founded in 1918 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ORKLA has a trailing twelve months EPS of kr4.37.
PE Ratio
ORKLA has a trailing twelve months price to earnings ratio of 17.51. Meaning, the purchaser of the share is investing kr17.51 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.77%.
More news about ORKLA.
5. SANOFI (SAN.PA)
3.55% Foward Dividend Yield
SANOFI’s last close was €102.44, 3.96% under its 52-week high of €106.66. Intraday change was 1.03%.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson's disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, SANOFI has a trailing twelve months EPS of €6.84.
PE Ratio
SANOFI has a trailing twelve months price to earnings ratio of 14.98. Meaning, the purchaser of the share is investing €14.98 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.77%.
Yearly Top and Bottom Value
SANOFI’s stock is valued at €102.44 at 17:50 EST, below its 52-week high of €106.66 and way higher than its 52-week low of €76.45.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 30, 2023, the estimated forward annual dividend rate is 3.56 and the estimated forward annual dividend yield is 3.55%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 10%, now sitting on 45.39B for the twelve trailing months.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SANOFI’s EBITDA is 25.72.
More news about SANOFI.
6. DEKUPLE (DKUPL.PA)
3.42% Foward Dividend Yield
DEKUPLE’s last close was €25.10, 30.66% below its 52-week high of €36.20. Intraday change was -1.18%.
ADLPartner SA provides marketing solutions in France and internationally. The company markets and sells press subscriptions; and offers cross-channel marketing solutions and insurance brokerage services. It also provides consulting and technology, marketing engineering, and creator of customer relation services. The company was founded in 1972 and is based in Montreuil, France. ADLPartner SA is a subsidiary of Sogespa SAS.
Earnings Per Share
As for profitability, DEKUPLE has a trailing twelve months EPS of €2.54.
PE Ratio
DEKUPLE has a trailing twelve months price to earnings ratio of 13.95. Meaning, the purchaser of the share is investing €13.95 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 37.16%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 17.9%, now sitting on 177.79M for the twelve trailing months.
Yearly Top and Bottom Value
DEKUPLE’s stock is valued at €25.10 at 17:50 EST, way under its 52-week high of €36.20 and higher than its 52-week low of €24.30.
More news about DEKUPLE.
7. CEGEDIM (CGM.PA)
2.63% Foward Dividend Yield
CEGEDIM’s last close was €19.00, 24.45% under its 52-week high of €25.15. Intraday change was 1.39%.
Cegedim SA operates as a technology and services company in the digital data flow management for healthcare ecosystem and B2B, and business software publisher for healthcare and insurance professionals worldwide. It operates in two divisions, Health Insurance, HR and e-Services; and Healthcare Professionals. The Health Insurance, HR and e-Services division markets various products and services to insurance companies, mutual insurers, personal protection insurers, and insurance brokers, as well as engages in the interactions between these entities and healthcare professionals. This division also provides solutions for hosting, HR and payroll management outsourcing, and electronic data exchange services. The Healthcare Professionals division offers management software, databases, and solutions to doctors, allied health professionals, pharmacists, and healthcare facilities. The company was incorporated in 1969 and is headquartered in Boulogne-Billancourt, France. Cegedim SA is a subsidiary of FCB SA.
Earnings Per Share
As for profitability, CEGEDIM has a trailing twelve months EPS of €1.
PE Ratio
CEGEDIM has a trailing twelve months price to earnings ratio of 19. Meaning, the purchaser of the share is investing €19 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.08%.
Dividend Yield
According to Morningstar, Inc., the next dividend payment is on Jun 29, 2022, the estimated forward annual dividend rate is 0.5 and the estimated forward annual dividend yield is 2.63%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, CEGEDIM’s stock is considered to be oversold (<=20).
More news about CEGEDIM.
